Hematologic Oncology

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Jorge E. Cortes, MD, has been an investigative leader for nearly 30 years in the development of numerous leukemia treatments.

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Red blood cells processed and stored in a hypoxic state maintain their integrity, which may reduce the risk of developing vaso-occlusion after red blood cell transfusion.

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Itolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem cell transplantation, and improve outcomes for these patients.

Preclinical evidence suggests that pairing KO-539 with targeted agents directed against BCL-2, BET, and CDK6 could result in superior efficacy against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.

Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.

Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.

The FDA has approved abatacept for the prophylaxis of acute graft-versus-host disease, in combination with certain immunosuppressants.

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo.

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.